SYT12 Antibody

What is SYT12 and what are its known functions?

SYT12 (Synaptotagmin XII) is a member of the synaptotagmin gene family that encodes proteins involved in calcium-dependent regulation of membrane trafficking during synaptic transmission. Studies in rat models have demonstrated that the SYT12 protein selectively modulates spontaneous synaptic-vesicle exocytosis . Additionally, SYT12 may play a role in regulating calcium-independent secretion in non-neuronal cells. It may be involved in Ca²⁺-dependent exocytosis of secretory vesicles through Ca²⁺ and phospholipid binding .

Recent research has identified additional roles for SYT12, including potential oncogenic functions in certain cancer types such as lung adenocarcinoma, where it has been shown to promote cell proliferation through activation of the PI3K/AKT/mTOR signaling pathway .

What are the common experimental applications for SYT12 antibodies?

SYT12 antibodies are utilized in multiple experimental techniques for detecting and analyzing SYT12 expression and function:

These applications allow researchers to investigate SYT12 expression patterns in normal tissues, examine alterations in disease states, and explore the protein's interactions with other molecules .

In which tissues and cell types is SYT12 predominantly expressed?

SYT12 shows notable expression in neural tissues, particularly in the brain. Research has confirmed expression in:

• Brain tissue (particularly high in mouse brain)

• Neuronal cell lines (such as SH-SY5Y cells)

• Various human tissues, with altered expression in certain pathological states

In cancer research, SYT12 has been found to be upregulated in several lung adenocarcinoma cell lines including A549, SPC-A-1, H1299, H1975, and PC9, compared to normal lung epithelial cells (HBE) . This differential expression pattern makes SYT12 a potential biomarker for certain malignancies and suggests tissue-specific regulatory mechanisms.

What criteria should be considered when selecting an SYT12 antibody for specific applications?

When selecting an SYT12 antibody for research applications, several critical factors should be evaluated:

• Antibody specificity: Confirm the antibody has been validated against specific epitopes of SYT12. For example, antibodies targeting amino acids 95-200 of human SYT12 (NP_001171351.1) have demonstrated good specificity .

• Species reactivity: Verify cross-reactivity with your experimental species. Available antibodies show reactivity with human, mouse, and rat SYT12, but epitope conservation varies across species .

• Clonality: Consider whether a polyclonal or monoclonal antibody best suits your application. Polyclonal antibodies often provide higher sensitivity but potentially lower specificity than monoclonals.

• Application validation: Select antibodies validated for your specific application (WB, IF, IHC, etc.).

• Host species: Consider the host species for compatibility with secondary detection systems and to avoid cross-reactivity in multi-labeling experiments.

• Epitope location: Different antibodies target distinct regions of SYT12 (e.g., AA 95-200, AA 301-350), which may affect recognition of specific isoforms or detection in different experimental conditions .

What are the optimal protocols for Western blot detection of SYT12?

For successful Western blot detection of SYT12, follow these optimization steps:

• Sample preparation: For neural tissues, use RIPA buffer with protease inhibitors. For cell lines, direct lysis in Laemmli buffer often yields good results.

• Protein loading: Load 20-40 μg of total protein per lane for cell lysates; 50-75 μg may be needed for tissue samples with lower SYT12 expression.

• Gel percentage: Use 10-12% SDS-PAGE gels for optimal resolution of SYT12 (molecular weight varies by isoform and post-translational modifications).

• Transfer conditions: Transfer to PVDF membranes at 100V for 60-90 minutes in standard Towbin buffer.

• Blocking: Block with 5% non-fat milk in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute SYT12 antibody 1:500-1:2400 (optimization required for each antibody) . Incubate overnight at 4°C.

• Detection: Use appropriate HRP-conjugated secondary antibodies and ECL detection systems.

• Expected band size: SYT12 typically appears at ~45-55 kDa, though this may vary based on isoform and post-translational modifications.

Positive controls should include mouse brain tissue or SH-SY5Y cells, which have demonstrated consistent SYT12 expression .

How can I optimize immunofluorescence protocols for SYT12 detection?

For optimal immunofluorescence detection of SYT12, consider these methodological refinements:

• Fixation: 4% paraformaldehyde for 15-20 minutes works well for most cell types. For sensitive epitopes, test milder fixation (2% PFA or methanol).

• Permeabilization: 0.1-0.3% Triton X-100 for 10 minutes is usually sufficient.

• Blocking: 5-10% normal serum from the same species as the secondary antibody, with 1% BSA in PBS.

• Primary antibody dilution: Start with 1:50-1:200 dilution and optimize . Incubate overnight at 4°C.

• Secondary antibody: Use highly cross-adsorbed secondary antibodies to minimize background.

• Counterstaining: DAPI for nuclear visualization; consider using neuronal or cell-type specific markers for co-localization studies.

• Controls: Include secondary-only controls and, if possible, SYT12-negative samples or SYT12-knockdown cells.

• Anticipated pattern: Expect punctate cytoplasmic staining in neuronal cells, with possible enrichment in synaptic regions.

For enhanced signal, consider using fluorophore-conjugated antibodies, such as AbBy Fluor® 488, 555, 680, or 750 conjugated anti-SYT12 antibodies if direct detection is preferred .

How can SYT12 antibodies be utilized for studying its role in cancer progression?

Recent research has identified SYT12 as a potential oncogene in lung adenocarcinoma (LUAD), making SYT12 antibodies valuable tools for cancer research . Advanced applications include:

• Prognostic biomarker studies: SYT12 expression correlates with tumor stage and prognosis in LUAD. Implement tissue microarray (TMA) analysis with standardized IHC scoring systems (0-300 scale) based on staining intensity (0-3) and percentage of positive cells (0-100%) .

• Signaling pathway analysis: Investigate SYT12's role in the PI3K/AKT/mTOR pathway by combining SYT12 detection with phospho-specific antibodies against PIK3R3, AKT (Ser473, Thr308), and mTOR. This approach elucidates the molecular mechanism by which SYT12 promotes cancer cell proliferation and migration .

• Functional studies: Pair SYT12 antibodies with knockdown/overexpression systems to validate phenotypic changes. Researchers have successfully used siRNA-mediated knockdown and plasmid-based overexpression of SYT12 to manipulate its levels in cancer cells and study resulting effects on proliferation and migration .

• Correlation with clinical parameters: Use multivariate analysis to correlate SYT12 expression with TNM staging, patient survival, and treatment response, as demonstrated in studies showing significant association between SYT12 expression and T stage and TNM stage in LUAD patients .

This multifaceted approach can reveal SYT12's potential as both a biomarker and therapeutic target in cancer research.

What methodologies can be employed to study the interaction between SYT12 and the PI3K/AKT/mTOR pathway?

To investigate SYT12's interaction with the PI3K/AKT/mTOR pathway, consider these advanced methodological approaches:

• Co-immunoprecipitation (Co-IP): Use SYT12 antibodies to pull down protein complexes, followed by Western blot analysis for PI3K pathway components (PIK3R3, PIK3R5, AKT, mTOR). This approach can identify direct protein-protein interactions.

• Phosphorylation analysis: Employ phospho-specific antibodies targeting PIK3R3, AKT (at Ser473 and Thr308), and mTOR to assess pathway activation status following SYT12 manipulation .

• Pathway inhibitor studies: Combine SYT12 overexpression with specific inhibitors of PI3K, AKT, or mTOR to determine pathway dependency. Analyze whether inhibitors can reverse the phenotypic effects of SYT12 overexpression.

• Proximity ligation assay (PLA): Use this technique to visualize and quantify SYT12's proximity to PI3K pathway components in situ with high sensitivity.

• Quantitative analysis: Implement densitometric analysis of Western blots to quantify phosphorylation changes. Research has shown that SYT12 manipulation affects phosphorylation of PIK3R3, activating the PI3K/AKT/mTOR signaling pathway .

This integrated approach provides comprehensive insights into how SYT12 interfaces with this critical signaling cascade in both normal and pathological contexts.

How can gene expression manipulation be combined with SYT12 antibody detection for mechanistic studies?

Combining gene expression manipulation with SYT12 antibody detection provides powerful insights into SYT12's cellular functions. Implementation strategies include:

• RNA interference (RNAi) validation: Design siRNAs targeting SYT12 (as demonstrated in lung cancer studies) and verify knockdown efficiency using SYT12 antibodies in Western blot. Quantitative analysis should show >70% reduction in protein levels for reliable phenotypic studies.

• Overexpression systems: Clone full-length human SYT12 cDNA into expression vectors (such as pEnter) , transfect target cells, and validate expression using antibodies against both native and tagged proteins (if tag sequences are incorporated).

• CRISPR/Cas9 genome editing: Generate SYT12 knockout or knock-in cell lines, using SYT12 antibodies to confirm complete protein elimination or modified protein expression.

• Rescue experiments: After SYT12 knockdown, introduce mutated versions (resistant to siRNA targeting) and use antibodies to verify expression levels match physiological conditions.

• Time-course analysis: Following manipulation, use SYT12 antibodies to monitor protein levels at multiple timepoints (24h, 48h, 72h post-transfection), correlating with phenotypic changes.

A comprehensive experimental design should include appropriate controls (empty vector, non-targeting siRNA) and quantitative validation of manipulation efficiency at both mRNA (qRT-PCR) and protein (Western blot with SYT12 antibodies) levels .

What are common challenges in SYT12 antibody-based detection and how can they be addressed?

Researchers frequently encounter several challenges when working with SYT12 antibodies:

• Low signal intensity: SYT12 may be expressed at modest levels in some tissues or cell types.

  • Solution: Try signal amplification systems (TSA), longer exposure times for Western blots, or consider using concentrated samples. Antibody dilutions of 1:500 for Western blot may provide better results than higher dilutions .

• Background or non-specific binding: Particularly problematic in immunohistochemistry applications.

  • Solution: Optimize blocking conditions (5-10% normal serum, 1% BSA); increase washing steps; try alternative blocking agents like fish gelatin or commercially available blockers designed to reduce background.

• Variability between antibody lots: Different lots may show varying sensitivity and specificity.

  • Solution: Validate each new lot against a previously successful lot; maintain consistent positive controls across experiments.

• Cross-reactivity with other synaptotagmin family members: The synaptotagmin family has multiple homologous members.

  • Solution: Select antibodies targeting unique regions of SYT12, such as those recognizing amino acids 95-200 of human SYT12 , which show lower homology to other family members.

• Post-translational modifications affecting epitope recognition: Phosphorylation may alter antibody binding.

  • Solution: Use multiple antibodies targeting different epitopes; consider phosphatase treatment of samples if phosphorylation is suspected to impact detection.

How can researchers validate the specificity of SYT12 antibodies in their experimental systems?

Rigorous validation of SYT12 antibody specificity is essential for reliable results. Implement these methodological approaches:

• Positive and negative controls: Include known SYT12-expressing tissues (mouse brain) and cell lines (SH-SY5Y) as positive controls. For negative controls, use tissues or cells with confirmed low/no SYT12 expression.

• Knockdown/knockout validation: Generate SYT12 knockdown samples using siRNA (as demonstrated in literature) or CRISPR/Cas9 systems. The antibody signal should decrease proportionally to knockdown efficiency.

• Overexpression validation: Express recombinant SYT12 in a system with low endogenous expression. The antibody should detect increased signal corresponding to overexpression levels.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide (if available) before applying to samples. This should eliminate specific binding.

• Multiple antibody comparison: Test antibodies from different sources or those targeting different epitopes of SYT12. Consistent patterns increase confidence in specificity.

• Molecular weight verification: Confirm that the detected band matches the expected molecular weight of SYT12 (~45-55 kDa, depending on isoforms and post-translational modifications).

• Mass spectrometry validation: For definitive confirmation, immunoprecipitate SYT12 using the antibody and analyze by mass spectrometry to verify protein identity.

What considerations are important when investigating SYT12 in different species models?

When studying SYT12 across different species models, researchers should consider these methodological factors:

• Sequence homology: While SYT12 is conserved across mammals, sequence variations exist. Human SYT12 shares approximately 89% amino acid identity with mouse SYT12 and 88% with rat SYT12. These differences may affect antibody cross-reactivity.

• Antibody selection: Choose antibodies validated for your species of interest. Many commercial antibodies are validated for human, mouse, and rat samples , but verification in your specific model is essential.

• Epitope conservation: Target epitopes with high cross-species conservation. Antibodies targeting amino acids 95-200 of human SYT12 have demonstrated cross-reactivity with mouse SYT12 , suggesting this region is relatively conserved.

• Isoform variations: Alternative splicing results in multiple transcript variants across species. Ensure your antibody detects the relevant isoforms in your model system.

• Application-specific validation: An antibody that works for Western blot in one species may not work for immunohistochemistry in another. Validate each application separately.

• Expression pattern differences: SYT12 expression patterns may vary between species. In humans, SYT12 has been studied in lung cancer , while in rodents, neuronal expression has been more extensively characterized.

• Sample preparation optimization: Fixation conditions, extraction buffers, and antigen retrieval methods may need species-specific optimization for optimal results.

How can SYT12 antibodies contribute to understanding its role as a potential biomarker in lung adenocarcinoma?

SYT12 antibodies are instrumental in exploring SYT12's potential as a biomarker in lung adenocarcinoma through several methodological approaches:

The established correlation between SYT12 expression and TNM stage in LUAD patients provides a foundation for developing SYT12 as a clinically relevant biomarker .

What methodological approaches can be used to investigate SYT12's role in synaptic transmission?

To investigate SYT12's function in synaptic transmission, researchers can implement these methodological strategies:

• Subcellular localization studies: Use immunofluorescence with SYT12 antibodies combined with synaptic markers (synaptophysin, PSD-95) to precisely localize SYT12 at synapses. High-resolution techniques such as STED or STORM microscopy can provide nanoscale localization.

• Electrophysiological correlations: Combine patch-clamp recordings with immunocytochemistry using SYT12 antibodies to correlate expression levels with synaptic function parameters (mEPSC frequency, paired-pulse ratio).

• Activity-dependent regulation: Examine changes in SYT12 expression and localization following neuronal activity manipulation (glutamate stimulation, KCl depolarization) using quantitative immunocytochemistry.

• Calcium-independent functions: As SYT12 may regulate calcium-independent secretion , design experiments comparing SYT12 localization and function in calcium-free versus calcium-containing conditions.

• Vesicle pool analysis: Use SYT12 antibodies in combination with FM dyes or pHluorin-based assays to determine which vesicle pools (readily releasable, reserve, spontaneous) are primarily regulated by SYT12.

• Interaction studies: Employ proximity ligation assays with SYT12 antibodies to identify molecular interactions with SNARE proteins and other synaptic components in situ.

These approaches can elucidate SYT12's specific contributions to spontaneous synaptic-vesicle exocytosis, as suggested by previous research .

How can advanced imaging techniques be combined with SYT12 antibodies for dynamic cellular studies?

Integrating advanced imaging techniques with SYT12 antibodies enables sophisticated analysis of protein dynamics. Implementation methodologies include:

• Live-cell imaging: Utilize fluorescently tagged anti-SYT12 antibody fragments (Fab) or nanobodies for real-time monitoring of SYT12 trafficking in living neurons or cancer cells.

• FRAP (Fluorescence Recovery After Photobleaching): Apply this technique with fluorescent anti-SYT12 antibodies to measure mobility and turnover rates of SYT12 at synaptic terminals or secretory sites.

• Single-molecule tracking: Implement quantum dot-conjugated anti-SYT12 antibodies for tracking individual SYT12 molecules with nanometer precision, revealing diffusion dynamics and confinement zones.

• FRET/FLIM analysis: Combine SYT12 antibodies labeled with donor fluorophores with acceptor-labeled antibodies against interaction partners to detect molecular associations and conformational changes.

• Correlative light-electron microscopy (CLEM): Use gold-conjugated SYT12 antibodies for immunoelectron microscopy following fluorescence imaging to correlate functional data with ultrastructural localization.

• Super-resolution microscopy: Implement STORM, PALM, or STED microscopy with appropriately labeled SYT12 antibodies (such as AbBy Fluor® 488, 555, 680, or 750 conjugated antibodies ) to achieve nanoscale resolution of SYT12 distribution.

• Light-sheet microscopy: Apply this technique with cleared tissue samples and fluorescent SYT12 antibodies for rapid 3D visualization of expression patterns across large tissue volumes.

These advanced approaches provide unprecedented insights into SYT12's spatiotemporal dynamics in both physiological and pathological contexts.